Terug
Ook genoteerd als
CMXHF
OTC
Dagbereik
€ 24,50
€ 25,31
52-Weeksbereik
€ 22,83
€ 44,86
Volume
48.668
50D / 200D Gem.
€ 27,97
/
€ 33,31
Vorige Slotkoers
€ 23,95
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (626 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 32,0 | 0,4 |
| P/B | 5,0 | 2,9 |
| ROE % | 16,4 | 3,7 |
| Net Margin % | 19,5 | 3,8 |
| Rev Growth 5Y % | 10,7 | 10,0 |
| D/E | 0,6 | 0,2 |
Belangrijkste Punten
Revenue grew 10,73% annually over 5 years — strong growth
ROE of 16,36% — decent returns on equity
Net margin of 19,46% shows strong profitability
Generating 2,54B in free cash flow
P/E of 32,02 — premium valuation
Revenue growth is decelerating — 1Y growth trails 5Y average by 6,47%
Groei
Revenue Growth (5Y)
10,73%
Revenue (1Y)4,26%
Earnings (1Y)13,63%
FCF Growth (3Y)67,29%
Kwaliteit
Return on Equity
16,36%
ROIC7,20%
Net Margin19,46%
Op. Margin19,18%
Veiligheid
Debt / Equity
0,59
Current Ratio2,46
Interest Coverage6,51
Waardering
P/E Ratio
32,02
P/B Ratio4,97
EV/EBITDA35,64
Dividend Yield0,01%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 4,26% | Revenue Growth (3Y) | 8,22% |
| Earnings Growth (1Y) | 13,63% | Earnings Growth (3Y) | 16,97% |
| Revenue Growth (5Y) | 10,73% | Earnings Growth (5Y) | 13,91% |
| Profitability | |||
| Revenue (TTM) | 15,43B | Net Income (TTM) | 3,00B |
| ROE | 16,36% | ROA | 7,62% |
| Gross Margin | 51,53% | Operating Margin | 19,18% |
| Net Margin | 19,46% | Free Cash Flow (TTM) | 2,54B |
| ROIC | 7,20% | FCF Growth (3Y) | 67,29% |
| Safety | |||
| Debt / Equity | 0,59 | Current Ratio | 2,46 |
| Interest Coverage | 6,51 | Dividend Yield | 0,01% |
| Valuation | |||
| P/E Ratio | 32,02 | P/B Ratio | 4,97 |
| P/S Ratio | 6,23 | PEG Ratio | 3,83 |
| EV/EBITDA | 35,64 | Dividend Yield | 0,01% |
| Market Cap | 96,11B | Enterprise Value | 105,45B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 15,43B | 14,80B | 13,17B | 10,49B | 10,27B |
| Net Income | 3,00B | 2,64B | 2,19B | 2,25B | 1,78B |
| EPS (Diluted) | 0,39 | 0,34 | 0,43 | 0,30 | 0,33 |
| Gross Profit | 7,95B | 7,56B | 6,71B | 5,66B | 5,74B |
| Operating Income | 2,96B | 3,81B | 2,90B | 2,92B | 2,59B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 39,40B | 38,02B | 36,23B | 28,35B | 13,63B |
| Total Liabilities | 18,00B | 18,62B | 18,41B | 13,77B | 7,34B |
| Shareholders' Equity | 19,34B | 17,36B | 15,79B | 14,58B | 6,29B |
| Total Debt | 11,50B | 12,18B | 12,23B | 9,66B | 4,36B |
| Cash & Equivalents | 2,16B | 1,66B | 1,55B | 10,44B | 1,36B |
| Current Assets | 11,85B | 10,77B | 9,26B | 16,46B | 5,55B |
| Current Liabilities | 4,81B | 4,95B | 4,61B | 7,11B | 2,33B |